Skip to main content
The Journal of Clinical Hypertension logoLink to The Journal of Clinical Hypertension
letter
. 2026 May 16;28(5):e70294. doi: 10.1111/jch.70294

Neprilysin and Hypertension: Cause, Consequence, or Marker?

Muhammad Qaseem 1,✉, Shehbaz Ali 1
PMCID: PMC13179713  PMID: 42142086

1.

Dear Editor‐in‐Chief,

Prof. Ji‐Guang Wang, we commend Hu et al. [1] for deserving our appreciation for their valuable work documented in the recent paper in the Journal of Clinical Hypertension. There are several aspects that should be explained in more detail, and it would be extremely helpful for clinicians to focus on them. The study was cross‐sectional; thus, it is unclear in which direction the observed association moved. Increased serum neprilysin (NEP) could be a cause of hypertension through increased natriuretic peptide degradation [2]; however, the reverse is equally possible: chronic hypertension or its management can change NEP. What should we do to determine the cause and consequence in this context? It is important to clarify the temporal relationship to gain a better insight into the pathophysiology of NEP in the development and progression of hypertension, given that the authors found a stepwise rise in the prevalence of hypertension across NEP quartiles even after multivariate adjustment.

The reported odds ratio (OR) is small (OR = 1.07 with an increase in NEP by log2). Although statistically significant when corrected for numerous confounders, is this effect size clinically meaningful for risk stratification or therapeutic decisions in clinical practice? In angiotensin receptor–neprilysin inhibitor (ARNI) therapy, even minor variations in circulating NEP could affect the blood pressure response [3, 4]. Nevertheless, most data on NEP are based on heart failure populations, and its specific contribution to arterial hypertension without heart failure is not well known. This difference is especially significant because ARNI agents are actively being examined outside of heart failure.

The authors conducted a sensitivity analysis that omitted participants who were on antihypertensive drugs. Nonetheless, no covariate of renal function (estimated glomerular filtration rate [eGFR]) was discussed, yet the kidney is the largest location of NEP expression and clearance [5]. Is it possible that part of this association is due to residual confounding by subclinical renal impairment? In addition, other significant confounders, such as dietary sodium or physical exercise levels, were described in more general terms and might have also impacted NEP levels and blood pressure control.

Finally, the genetic correlations (e.g., rs9864287) were no longer statistically significant following false‐discovery‐rate correction. Are these signals still suggestive, or would they be considered negative findings, considering the sample size? It would be intriguing to learn the extent to which larger sample sizes or other ethnic groups could provide stronger genetic signals. Again, it is a credit to Hu et al. that they have provided an expert synthesis and have started a critical discussion on neprilysin in the management of hypertension. Further prospective and mechanistic studies are essential to clarify whether circulating NEP can be used as a new biomarker or even a therapeutic target in patients with arterial hypertension.

Author Contributions

All authors contributed to the planning, writing, and revision of the manuscript.

Funding

The authors have nothing to report.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.

References

  • 1. Hu J., Duan J., Jing J., et al., “Associations of Neprilysin and Its Coding Gene Variation With Hypertension in Chinese Adults,” Journal of Clinical Hypertension 28, no. 3 (2026): e70228, 10.1111/jch.70228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Vodovar N., Séronde M. F., Laribi S., et al., “Elevated Plasma B‐Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure,” Journal of the American College of Cardiology: Heart Failure 3, no. 8 (2015): 629–636, 10.1016/j.jchf.2015.03.011. [DOI] [PubMed] [Google Scholar]
  • 3. McMurray J. J. V., Packer M., Desai A. S., et al., “Angiotensin–Neprilysin Inhibition Versus Enalapril in Heart Failure,” New England Journal of Medicine 371, no. 11 (2014): 993–1004, 10.1056/NEJMoa1409077. [DOI] [PubMed] [Google Scholar]
  • 4. Solomon S. D., McMurray J. J. V., Anand I. S., et al., “Angiotensin–Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction,” New England Journal of Medicine 381, no. 17 (2019): 1609–1620, 10.1056/NEJMoa1908655. [DOI] [PubMed] [Google Scholar]
  • 5. Bayes‐Genis A., Barallat J., and Richards A. M., “A Test in Context: Neprilysin: Function, Inhibition, and Biomarker,” Journal of the American College of Cardiology 68, no. 6 (2016): 639–653, 10.1016/j.jacc.2016.04.060. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.


Articles from The Journal of Clinical Hypertension are provided here courtesy of Wiley

RESOURCES